RESUMO
BACKGROUND AND OBJECTIVES: Two External Quality Assessment Programmes (EQAPs) were run in 2008 and 2009 to evaluate the proficiency of blood centres in detecting, by nucleic acid amplification techniques (NAT), the possible contamination of plasma with hepatitis C virus (HCV), human immunodeficiency virus (HIV) and hepatitis B virus (HBV). MATERIALS AND METHODS: In the EQAP-2008, three customized panels were designed; each containing positive samples with a viral nominal concentration for the three viruses of about three times the 95% DL of the respective commercial NAT assay. In the EQAP-2009, the proficiency of the participants was evaluated with a single panel, independently on the NAT method used. RESULTS: While 84% (102/122) of the participants in the EQAP-2008 correctly identified the positive and negative samples of the panels, in the EQAP-2009 the percentage of proficient laboratories increased to 97% (118/122). Most importantly, in this 2-year experience, we observed a decrease in the number of pre-/postanalytical errors, from 14 in 2008 to two in 2009. CONCLUSIONS: The design of these two EQAPs allowed participants to assess the performance of the NAT methods applied in their routine screening of blood donations, not only with respect to analytical errors but also to human errors that, despite the high level of automation reached by NAT methods, can still occur.
Assuntos
Bancos de Sangue , DNA Viral/sangue , HIV , Hepacivirus , Vírus da Hepatite B , Técnicas de Amplificação de Ácido Nucleico/normas , Garantia da Qualidade dos Cuidados de Saúde , RNA Viral/sangue , Feminino , Humanos , Itália , Masculino , Técnicas de Amplificação de Ácido Nucleico/métodos , Sensibilidade e EspecificidadeRESUMO
BACKGROUND AND OBJECTIVES: In this EQA study a novel approach was used to assess the performance of blood centres and blood product manufacturers in detecting the possible contamination of plasma with HCV, HIV and HBV by NAT. MATERIALS AND METHODS: A panel of 12 samples, three negative and three positive for each virus, was distributed to the EQA participants. The positive samples were prepared, using the respective WHO standards, in order to obtain a viral concentration of about three times the 95% DL of the methods most commonly used by laboratories involved in blood screening by NAT. Participants were requested to test each sample of the panel on different days, possibly by different operators using their routine NAT assay. RESULTS: Overall, the participants' performance was satisfactory. In particular, 49 of the 59 participants (83%) were able to correctly identify all samples. Regarding the remaining 10 laboratories, in three cases a deviation from the laboratory's procedure that could be attributed to an operator's mistake was observed, in two cases a possible cross-contamination occurred while in the remaining five cases the failure to detect the positive samples couldn't be ascribed to any relevant deviation in the laboratory's procedure. CONCLUSIONS: The novel design of this EQA study allowed participants to verify their day by day activity as the study was carried out in the context of their routine testing. Under these conditions, it was demonstrated that, despite the high level of automation reached by NAT assays, human errors can still occur.
Assuntos
HIV/isolamento & purificação , Hepacivirus/isolamento & purificação , Vírus da Hepatite B/isolamento & purificação , Técnicas de Amplificação de Ácido Nucleico/métodos , Controle de Qualidade , DNA Viral/sangue , HIV/genética , Hepacivirus/genética , Vírus da Hepatite B/genética , Humanos , Variações Dependentes do Observador , RNA Viral/sangueAssuntos
Doenças dos Bovinos/diagnóstico , Cistite/veterinária , Animais , Animais Recém-Nascidos , Bovinos , Doenças dos Bovinos/diagnóstico por imagem , Doenças dos Bovinos/patologia , Cistite/complicações , Cistite/diagnóstico , Diagnóstico Diferencial , Endoscopia/veterinária , Feminino , Necrose/complicações , Necrose/diagnóstico , Necrose/veterinária , Ruptura Espontânea/complicações , Ruptura Espontânea/veterinária , Ultrassonografia , Bexiga Urinária/patologiaRESUMO
BACKGROUND AND OBJECTIVES: This External Quality Assessment (EQA) study was aimed at assessing the proficiency of blood centres and blood product manufacturers in detecting, by nucleic acid amplification technology (NAT), the possible contamination of plasma with hepatitis C virus (HCV), human immunodeficiency virus (HIV) and hepatitis B virus (HBV). MATERIALS AND METHODS: Three independent panels, one for each virus, were prepared at the Istituto Superiore di Sanità (ISS) by diluting the respective reference preparations. NAT methods used by the EQA participants included polymerase chain reaction (PCR) assays by Roche, transcription-mediated amplification (TMA) assays by Chiron and in-house PCR assays. RESULTS: Forty-three of the 45 participants (95.6%) in the HCV EQA/5 who used a validated method were consistently able to detect a nominal concentration of 100 IU/ml for all six major genotypes. In the case of the HIV EQA/1, all 35 participants detected the samples containing 1000 IU/ml HIV, while five (14.3%) did not identify the samples containing 100 IU/ml HIV. With respect to the HBV EQA/1, all 16 participants correctly identified the positive samples containing either 1000 IU/ml or 100 IU/ml HBV. No false-positive results were observed with any of the three panels. CONCLUSIONS: The HCV EQA/5 showed an improved proficiency of laboratories as compared with the HCV EQA/4. In fact, HCV genotypes 1, 2, 3 and 5 were correctly identified in 100% of the assays and genotypes 4 and 6 in 97.8% of the assays. While most of the participants in the HIV EQA/1 showed a good level of proficiency, an excellent performance was shown by all participants in the HBV EQA/1.
Assuntos
HIV/isolamento & purificação , Hepacivirus/isolamento & purificação , Vírus da Hepatite B/isolamento & purificação , Técnicas de Amplificação de Ácido Nucleico/normas , Plasma/virologia , Reações Falso-Positivas , Humanos , Reação em Cadeia da Polimerase/normas , Garantia da Qualidade dos Cuidados de SaúdeAssuntos
Doadores de Sangue , Infecções por Herpesviridae/epidemiologia , Herpesvirus Humano 8 , Hospedeiro Imunocomprometido , Imunoglobulinas Intravenosas , Infecções por Herpesviridae/etiologia , Infecções por Herpesviridae/imunologia , Humanos , Imunoglobulinas Intravenosas/efeitos adversos , Itália , Fatores de RiscoAssuntos
Anticorpos Anti-Hepatite/sangue , Antígenos de Hepatite/imunologia , Hepatite Viral Humana/prevenção & controle , Imunoglobulinas Intravenosas/imunologia , Imunoglobulinas/imunologia , Glicoproteínas de Membrana/imunologia , Proteínas do Envelope Viral/imunologia , Contaminação de Medicamentos , HumanosRESUMO
The presence of anti-HCV antibodies in immunoglobulin preparations was investigated by recombinant immunoblot assay (RIBA) and enzyme immunoassay (EIA). While EIA was found to be suitable for detecting anti-HCV antibodies in immunoglobulin preparations, the RIBA could not be used without modifying the standard procedure developed for use with human sera. The two modifications were: (1) incubation with the anti-human IgG conjugate in a single test tube for each strip, instead of in a common vessel; (2) removal of the conjugate after 15 min and its replacement with fresh conjugate for a second 15 min incubation period. Thirty-six immunoglobulin preparations were tested using this modified procedure. Twenty-nine out of 31 (93.5%) preparations received in 1992 were anti-HCV positive, whereas the five immunoglobulin preparations received in 1993 were negative. These results were compared with those obtained on the same samples with the EIA. The percentage of samples positive with EIA was 74.2%. The difference between the results obtained with modified RIBA and EIA was statistically significant (P < 0.05).
Assuntos
Anticorpos Anti-Hepatite/análise , Immunoblotting , Anticorpos Anti-Hepatite C , Humanos , Técnicas Imunoenzimáticas , Testes de Neutralização , Kit de Reagentes para Diagnóstico , Proteínas Recombinantes/análise , Proteínas Recombinantes/imunologia , Sensibilidade e EspecificidadeRESUMO
Four hundred and sixty-eight immunoglobulin preparations, produced between 1969 and 1989, were examined for anti-HIV antibodies by means of two competitive immunoenzymatic assays and the Western blot test. This study refers the results obtained by the three different methods. Such results show that the detection of anti-HIV antibodies in immunoglobulins may be performed on a routine basis using commercial kits intended for human sera. The meaning of the test and the role of antibodies against the HIV envelope proteins are emphasized.